inclusion criteria: age 1. are ≥18 years of age at the time of randomization disease characteristics 2. are currently hospitalized since less or equal than 3 days for covid-19 respiratory illness 3. must have a positive sars-cov-2 viral infection determination prior to randomisation. for the phase 2 portion of the study only, the test must be performed within 24 hours before randomisation. test can be a pcr or an antigen test originated from the institution or any government approved testing site. if the original test result is greater than 24 hours from randomisation, a rapid antigen must be performed at bedside by the study team to determine eligibility sex 4. are men or non-pregnant women reproductive and contraceptive agreements and guidance is provided in appendix 2. contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies. study procedures 5. understand and agree to comply with planned study procedures 6. agree to the collection of nasopharyngeal swabs and venous blood informed consent 7. the participant or legally authorized representative give signed informed consent

inclusion criteria: age 1. are ≥18 years of age at the time of randomization disease characteristics 2. are currently hospitalized since less or equal than 3 days for covid-19 respiratory illness 3. must have a positive sars-cov-2 viral infection determination prior to randomisation. for the phase 2 portion of the study only, the test must be performed within 24 hours before randomisation. test can be a pcr or an antigen test originated from the institution or any government approved testing site. if the original test result is greater than 24 hours from randomisation, a rapid antigen must be performed at bedside by the study team to determine eligibility sex 4. are men or non-pregnant women reproductive and contraceptive agreements and guidance is provided in appendix 2. contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies. study procedures 5. understand and agree to comply with planned study procedures 6. agree to the collection of nasopharyngeal swabs and venous blood informed consent 7. the participant or legally authorized representative give signed informed consent

inclusion criteria: age are ≥18 years of age at the time of randomization disease characteristics are currently hospitalized since less or equal than 3 days for covid-19 respiratory illness must have a positive sars-cov-2 viral infection determination prior to randomisation. for the phase 2 portion of the study only, the test must be performed within 24 hours before randomisation. test can be a pcr or an antigen test originated from the institution or any government approved testing site. if the original test result is greater than 24 hours from randomisation, a rapid antigen must be performed at bedside by the study team to determine eligibility sex are men or non-pregnant women reproductive and contraceptive agreements and guidance is provided in appendix 2. contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies. study procedures understand and agree to comply with planned study procedures agree to the collection of nasopharyngeal swabs and venous blood informed consent the participant or legally authorized representative give signed informed consent

inclusion criteria: age are ≥18 years of age at the time of randomization disease characteristics are currently hospitalized since less or equal than 3 days for covid-19 respiratory illness must have a positive sars-cov-2 viral infection determination prior to randomisation. for the phase 2 portion of the study only, the test must be performed within 24 hours before randomisation. test can be a pcr or an antigen test originated from the institution or any government approved testing site. if the original test result is greater than 24 hours from randomisation, a rapid antigen must be performed at bedside by the study team to determine eligibility sex are men or non-pregnant women reproductive and contraceptive agreements and guidance is provided in appendix 2. contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies. study procedures understand and agree to comply with planned study procedures agree to the collection of nasopharyngeal swabs and venous blood informed consent the participant or legally authorized representative give signed informed consent

inclusion criteria: age are ≥18 years of age at the time of randomization disease characteristics are currently hospitalized since less or equal than 3 days for covid-19 respiratory illness must have a positive sars-cov-2 viral infection determination prior to randomisation sex are men or non-pregnant women reproductive and contraceptive agreements and guidance is provided in appendix 2. contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies. study procedures understand and agree to comply with planned study procedures agree to the collection of nasopharyngeal swabs and venous blood informed consent the participant or legally authorized representative give signed informed consent

inclusion criteria: age are ≥18 years of age at the time of randomization disease characteristics are currently hospitalized since less or equal than 3 days for covid-19 respiratory illness must have a positive sars-cov-2 viral infection determination prior to randomisation sex are men or non-pregnant women reproductive and contraceptive agreements and guidance is provided in appendix 2. contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies. study procedures understand and agree to comply with planned study procedures agree to the collection of nasopharyngeal swabs and venous blood informed consent the participant or legally authorized representative give signed informed consent